Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
Objectives: ANCA-associated vasculitis (AAV) can affect all age groups. We aimed to show that differences in disease presentation and 6 month outcome between younger- A nd older-onset patients are still incompletely understood. Methods: We included patients enrolled in the Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study between October 2010 and January 2017 with a diagnosis of AAV. We divided the population according to age at diagnosis: <65 years or ≥65 years. We adjusted associations for the type of AAV and the type of ANCA (anti-MPO, anti-PR3 or negative). Results: A total of 1338 patients with AAV were included: 66% had disease onset at <65 years of age [female 50%; mean age 48.4 years (s.d. 12.6)] and 34% had disease onset at ≥65 years [female 54%; mean age 73.6 years (s.d. 6)]. ANCA (MPO) positivity was more frequent in the older group (48% vs 27%; P = 0.001). Younger patients had higher rates of musculoskeletal, cutaneous and ENT manifestations compared with older patients. Systemic, neurologic,cardiovascular involvement and worsening renal function were more frequent in the older-onset group. Damage accrual, measured with the Vasculitis Damage Index (VDI), was significantly higher in older patients, 12% of whom had a 6 month VDI ≥5, compared with 7% of younger patients (P = 0.01). Older age was an independent risk factor for early death within 6 months from diagnosis [hazard ratio 2.06 (95% CI 1.07, 3.97); P = 0.03]. Conclusion: Within 6 months of diagnosis of AAV, patients >65 years of age display a different pattern of organ involvement and an increased risk of significant damage and mortality compared with younger patients.
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes / Monti S., Craven A., Klersy C., Montecucco C., Caporali R., Watts R., Merkel P.A., Luqmani R., Achilleos K., Adler M., Alba M.A., Albert D.A., Alibaz-Oner F., Allcoat P., Amano K., Amarasuriya M., Amudala N.A., Andrews J., Archer A.M., Arimura Y., et al.. - In: RHEUMATOLOGY. - ISSN 1462-0324. - ELETTRONICO. - 60:(2021), pp. 617-628. [10.1093/rheumatology/keaa215]
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes
Monti S.;Craven A.;Klersy C.;Montecucco C.;Caporali R.;Watts R.;Merkel P. A.;Luqmani R.;Achilleos K.;Adler M.;Alba M. A.;Albert D. A.;Alibaz-Oner F.;Allcoat P.;Amano K.;Amarasuriya M.;Amudala N. A.;Andrews J.;Archer A. M.;Arimura Y.;Atukorala I.;Azevedo E.;Bajad S.;Baldwin C.;Barra L. J.;Baslund B.;Basu N.;Baykal M.;Berger C.;Berglin E.;Besada E.;Bhardwaj M.;Bischof A.;Blockmans D.;Blood J.;Draibe J. B.;Brand S.;Brandao M.;Bruce I. N.;Butler A.;Calabrese L. H.;Ferrer D. C.;Carette S.;Carmona D.;Ceunen H.;Chakravarty K.;Chapman P. T.;Chocova Z.;Chung S. A.;Ci W.;Cid M. C.;Clark T. M.;Clarkson M. R.;De Jesus Contreras-Rodriguez F.;Conway R.;Cooke K.;Viros X. C.;Cordeiro A.;Costa A.;Craven A.;Culfear K.;Daikeler T.;Danda D.;Das S. K.;Dasgupta B.;De Castro A. M.;Dehghan N.;Devassy R.;Dhindsa N.;Diamantopoulos A. P.;Direskeneli H.;Dobashi H.;Juan D.;Durrani M.;Edelsten C.;Eifert J.;Elhayek S.;Elsideeg S.;Endo T.;Erden A.;Erer B.;Eriksson P.;Erturk Z.;Espigol-Frigole G.;Felicetti M.;Ferraro A.;Ferro J. M.;Fifi-Mah A.;Flores-Suarez L. F.;Flossmann O.;Flynn D.;Fonseca J. E.;Foot J.;Foote M.;Forbess L.;Fujimoto S.;Fukuoka K.;Furtado C.;Furuta S.;Gaffo A. L.;Gallagher P.;Gao N.;Gatenby P.;Gendi N.;Geraldes R.;Gerits A.;Gioffredi A.;Gomples L.;Goncalves M. J.;Gondo P.;Graham A.;Grainger R.;Gray D. T.;Grayson P. C.;Griffiths L.;Guo Y.;Gupta R.;Gylling M.;Hajj-Ali R. A.;Hammam N.;Harigai M.;Hartley L.;Haslett J.;Hassan A.;Hatemi G.;Hellmich B.;Henckaerts L.;Henes J. C.;Hepburn J.;Herd V.;Hess C.;Hill C.;Hinojosa-Azaola A.;Hirahashi J.;Hirano F.;Hocevar A.;Holle J.;Hollinger N.;Homma S.;Howard T.;Hoyles R. K.;Hruskova Z.;Hutcheon G.;Ignacak M.;Igney-Oertel A.;Ikeda K.;Ikegaya N.;Jagadeesh S.;Jaquith J.;Jayne D. R. W.;Jewell T.;Jones C.;Joshi A.;Kalyoncu U.;Kamall S.;Kamath S.;Lai K. S.;Kaname S.;Kanchinadham S.;Karadag O.;Karube M.;Kaszuba M.;Kaur R.;Kawakami T.;Kawashima S.;Khalidi N.;Khan A.;Kikuchi M.;Kilic L.;Kimura M.;King M. J.;Klapa S.;Klocke R.;Kobayashi T.;Kobayashi S.;Komagata Y.;Kronbichler A.;Kuczia P.;Kumar M. S.;Kurosawa M.;Lamprecht P.;Langford C. A.;Lanyon P.;Laversuch C.;Lee S. J.;Leoni S.;Li J.;Liang K.;Liang P.;Liao H.;Lee L. A.;Luqmani R. A.;Lyle A.;Macdonald M.;Mackie S. L.;Madden L.;Magliano M.;Makino H.;Makol A.;Malaiya R.;Malaviya A.;Manthri R.;Maritati F.;Da Silva A. M.;Mason J. C.;Matara C.;Matsui K.;Matteson E. L.;Mcbride D.;Mccullough K.;Mcgeoch L.;Mclaren J.;Mcmillian C.;Mendiratta N.;Menon A.;Merinopoulos D.;Merkel P. A.;Merkel P.;Messier S.;Micheletti R. G.;Mills K.;Milman N.;Minoda M.;Minz R. W.;Mock C.;Mohammad A. J.;Moiseev S.;Moitinho M.;Molloy E.;Monach P. A.;Montgomery M.;Moosig F.;Moradizadeh M.;Morgan M.;Morgan A. W.;Morgan A. -M.;Muir A.;Mukhtyar C.;Muller A.;Muratore F.;Muso E.;Nada R.;Nakajima H.;Nakajima T.;Nakano H.;Nandagudi A.;Neumann T.;Ng Y. F.;Ng K. H.;Nogueira E. L.;Nolkha N.;Nordstrom D.;Novikov P.;Nugaliyadde A.;O'donnell J. L.;O'donoghue J.;O'neill L.;O'riordan E.;Oatley M.;Okubo K.;Oliva E.;Oshikawa H.;Ota Y.;Padoan R.;Pagnoux C.;Pan L.;Panaritis K.;Park J. K.;Patel S.;Patil P.;Pazzola G.;Peall A.;Pearce F.;Pehlevan S.;Pereira L.;Pettersson T.;Pineau C. A.;Pirila L.;Poglodek B.;Ponte C.;Prieto-Gonzalez S.;Priya S. R.;Purewal B.;Purschke S.;Putaala J.;Quickert S.;Quincey V.;Raghuvanshi S.;Rajasekhar L.;Ranganathan D.;Rathi M.;Rees D.;Rees F.;Renken U.;Restuccia G.;Rhee R. L.;Rice B.;Robins D.;Robson J.;Rodrigues M.;Romao V. C.;Rotar C.;Ruediger C.;Rutgers A.;Sa A. C.;Saavedra M. J.;Sada K. -E.;Sahbudin I.;Salvarani C.;Sandhu N.;Santos E.;Sato Y.;Schafer V. S.;Schiavon F.;Schmidt W. A.;Segelmark M.;Shahin A.;Sharma A.;Shotton J.;Silva C.;Singer O. G.;Sivasuthan G.;Smolen S.;Solanich-Moreno X.;Boixader L. S.;Song Y. W.;Springer J.;Sreih A. G.;Srivastava R.;Stamp L. K.;Stevens R.;Strbian D.;Sugino K.;Sunderkotter C.;Suppiah R.;Suzuki K.;Suzuki K.;Szekanecz Z.;Sznajd J.;Taimen K.;Tak P. P.;Takeuchi T.;Takizawa N.;Tames L.;Tan B. E.;Tanaka M.;Tang M. W.;Tatlisumak T.;Tesar V.;Thomas A.;Tian X.;Tokunaga K.;Tombetti E.;Tomsic M.;Toz B.;Tsukamoto T.;Uchida S.;Unal A. U.;Urban M. L.;Usui J.;Vaglio A.;Venkatachalam S.;Vermaak E.;Viswanath V.;Wada T.;Wagh S.;Wallace D. J.;Walters G.;Walz B.;Wan J.;Wang T.;Wang G.;Warrington K. J.;Watts R. A.;Wawrzycka-Adamczyk K.;Weeratunga P.;Weisman M. H.;Wickramasinghe S.;Williams M.;Williams M.;Wojcik K.;Woodruff L.;Xenitidis T.;Yamada H.;Yamagata K.;Yee C. -S.;Yoon M.;Yoshida K.;Yoshifuji H.;Ytterberg S. R.;Yumura W.;Zayed H.;Zeng X.;Zhao M. -H.;Zugaj A.;Zuk J.
2021
Abstract
Objectives: ANCA-associated vasculitis (AAV) can affect all age groups. We aimed to show that differences in disease presentation and 6 month outcome between younger- A nd older-onset patients are still incompletely understood. Methods: We included patients enrolled in the Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study between October 2010 and January 2017 with a diagnosis of AAV. We divided the population according to age at diagnosis: <65 years or ≥65 years. We adjusted associations for the type of AAV and the type of ANCA (anti-MPO, anti-PR3 or negative). Results: A total of 1338 patients with AAV were included: 66% had disease onset at <65 years of age [female 50%; mean age 48.4 years (s.d. 12.6)] and 34% had disease onset at ≥65 years [female 54%; mean age 73.6 years (s.d. 6)]. ANCA (MPO) positivity was more frequent in the older group (48% vs 27%; P = 0.001). Younger patients had higher rates of musculoskeletal, cutaneous and ENT manifestations compared with older patients. Systemic, neurologic,cardiovascular involvement and worsening renal function were more frequent in the older-onset group. Damage accrual, measured with the Vasculitis Damage Index (VDI), was significantly higher in older patients, 12% of whom had a 6 month VDI ≥5, compared with 7% of younger patients (P = 0.01). Older age was an independent risk factor for early death within 6 months from diagnosis [hazard ratio 2.06 (95% CI 1.07, 3.97); P = 0.03]. Conclusion: Within 6 months of diagnosis of AAV, patients >65 years of age display a different pattern of organ involvement and an increased risk of significant damage and mortality compared with younger patients.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1237441
Citazioni
ND
40
37
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
